News & Events about Aeglea Biotherapeutics Inc.
Investment analysts at StockNews.com initiated coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research report issued on Wednesday. The firm set a hold rating on the biotechnology companys stock. AGLE has been the subject of a number of other ...
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of...
StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research note released on Monday morning. The firm issued a hold rating on the biotechnology companys stock. AGLE has been the topic of several other research reports. Piper Sandler increased their target ...
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire AUSTIN, Texas, Jan. 6, 2023 Streamlining of organization to focus on near-term deliverables...
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 611,000 shares, an increase of 17.8% from the October 15th total of 518,700 shares. Based on an average daily trading ...